Thermo Fisher Scientific Opens New Manufacturing Facility in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thermo Fisher Scientific Opens New Manufacturing Facility in China


ePT--the Electronic Newsletter of Pharmaceutical Technology

Thermo Fisher Scientific has officially opened its new manufacturing facility in Suzhou, China. The company has invested nearly $20 million in the 12,000-m2 (129,167 ft2) plant, which will manufacture life-sciences consumables and equipment as well as establish local production capabilities to meet increasing customer demand in China and other regions in Asia Pacific. The new facility will serve the life-sciences and pharmaceutical industries, including research, diagnostics, and bioproduction, and customers in the chemical, environmental, and electronics industries. More than 150 employees will be housed in this facility and there is room for expansion.

In a press statement, Marc Casper, president and CEO of Thermo Fisher Scientific said, “China is one of our fastest-growing markets and has been a key contributor to our success. The Suzhou facility builds on our well-established presence in China and is an important next step as we closely align our depth of capabilities with China’s five-year plan to develop strategic industries, including pharmaceutical, healthcare, and environmental.”

Thermo Fisher entered the Chinese market 30 years ago and will manufacture plastic labware and consumables in Suzhou, including sample preparation products and filterware, as well as laboratory refrigerators, freezers, incubators, and centrifuges. The new facility will adopt best global and local manufacturing practices, including ISO9001, ISO14001, and ISO13485 standards to ensure an environmentally friendly and safe work environment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here